Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 14/20 | 0.43 |
| ▸ | CCR4 | P51679 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6428725 | 0.81 | ALDH1A1 (0.59) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL6427333 | 0.79 | ALDH1A1 (0.44) | NPC1RAB9AALDH1A1L3MBTL1 | |
| SCHEMBL6504719 | 0.73 | HPGD (0.49) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL1605522 | 0.72 | KDM4C (0.38) | ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL6393708 | 0.72 | NPC1 (0.41) | NPC1RAB9AP2RX7ALDH1A1MEN1 | |
| SCHEMBL6426489 | 0.71 | P2RX7 (0.43) | NPC1RAB9AP2RX7ALDH1A1KMT2A | |
| SCHEMBL6428045 | 0.71 | PKM (0.40) | ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL6386550 | 0.70 | NAMPT (0.42) | ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL13121967 | 0.70 | KMT2A (0.33) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL6393753 | 0.69 | SLC6A2 (0.35) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | NPC1 277/4885RAB9A 2649/4885P2RX7 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.